Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Abstract 1381: BCL-2 selective inhibitor venetoclax combined with topoisomerase I inhibitor irinotecan is effective in small cell lung cancer (SCLC)

Yanli Xing, Krista M. Dalton, Jane L. Roberts, Anthony C. Faber

Cancer Res (2025) 85 (8_Supplement_1): 1381.

https://doi.org/10.1158/1538-7445.AM2025-1381

Published: 21 April 2025

View articletitled, Abstract 1381: BCL-2 selective inhibitor venetoclax combined with topoisomerase I inhibitor irinotecan is effective in small cell lung cancer (SCLC)

Journal Articles

A Critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment

Tareq Saleh, Edward F. Greenberg, Anthony C. Faber, Hisashi Harada, David A. Gewirtz

Cancer Res OF1–OF14.

https://doi.org/10.1158/0008-5472.CAN-24-2219

Published: 21 April 2025

View articletitled, A Critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment

Journal Articles

The Innate Immune System and the TRAIL–Bcl-XL Axis Mediate a Sex Bias in Lung Cancer and Confer a Therapeutic Vulnerability in Females

Cancer Res (2024) 84 (24): 4140–4155.

https://doi.org/10.1158/0008-5472.CAN-24-0585

Published: 16 December 2024

View articletitled, The Innate Immune System and the TRAIL–Bcl-XL Axis Mediate a Sex Bias in Lung Cancer and Confer a Therapeutic Vulnerability in Females

Includes: Supplementary data

Journal Articles

Abstract 5976: R9: A novel NuRD complex inhibitor for targeted therapy in triple negative breast cancer (TNBC)

Kun Zhang, Sheeba Jacob, Mikhail Dozmorov, Ivan Babic, Elmar Nurmemmedov, Anthony C. Faber

Cancer Res (2024) 84 (6_Supplement): 5976.

https://doi.org/10.1158/1538-7445.AM2024-5976

Published: 22 March 2024

View articletitled, Abstract 5976: R9: A novel NuRD complex inhibitor for targeted therapy in triple negative breast cancer (TNBC)

Journal Articles

Abstract 5119: Exploring the relationship between metabolism and the epigenome in MYCN-amplified neuroblastoma

Krista M. Dalton, Timothy L. Lochmann, Colin Coon, Marissa L. Calbert, Mikhail Dozmorov, Lisa Shock, Jennifer Koblinski, Anthony C. Faber

Cancer Res (2024) 84 (6_Supplement): 5119.

https://doi.org/10.1158/1538-7445.AM2024-5119

Published: 22 March 2024

View articletitled, Abstract 5119: Exploring the relationship between metabolism and the epigenome in MYCN-amplified neuroblastoma

Journal Articles

Abstract 7071: Pharmacological targeting of SUMOylation leads to cBAF complex stabilization and disruption of the synovial sarcoma signature

Konstantinos V. Floros, Jinxiu Li, Jane L. Roberts, Richard Kurupi, Carter K. Fairchild, Bin Hu, Yanli Xing, Krista M. Dalton, Sosipatros A. Boikos, Angeliki M. Stamatouli, Mikhail G. Dozmorov, Jennifer E. Koblinski, Kevin B. Jones, Senthil K. Radhakrishnan, Anthony C. Faber

Cancer Res (2024) 84 (6_Supplement): 7071.

https://doi.org/10.1158/1538-7445.AM2024-7071

Published: 22 March 2024

View articletitled, Abstract 7071: Pharmacological targeting of SUMOylation leads to cBAF complex stabilization and disruption of the synovial sarcoma signature

Journal Articles

Abstract 362: MYCN-amplified neuroblastoma is addicted to iron and vulnerable to ferroptosis

Konstantinos V. Floros, Mia O. Johnson-Berro, Richard Kurupi, Carter K. Fairchild, Krista Dalton, Bin Hu, Madhavi Puchalapalli, Mikhail G. Dozmorov, Jennifer E. Koblinski, James A. Olzmann, Lauren A. Cowart, Anthony C. Faber

Cancer Res (2022) 82 (12_Supplement): 362.

https://doi.org/10.1158/1538-7445.AM2022-362

Published: 15 June 2022

View articletitled, Abstract 362: MYCN-amplified neuroblastoma is addicted to iron and vulnerable to ferroptosis

Journal Articles

MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis

Konstantinos V. Floros, JinYang Cai, Sheeba Jacob, Richard Kurupi, Carter K. Fairchild, Mayuri Shende, Colin M. Coon, Krista M. Powell, Benjamin R. Belvin, Bin Hu, Madhavi Puchalapalli, Sivapriya Ramamoorthy, Kimberly Swift, Janina P. Lewis, Mikhail G. Dozmorov, John Glod, Jennifer E. Koblinski, Sosipatros A. Boikos, Anthony C. Faber

Cancer Res (2021) 81 (7): 1896–1908.

https://doi.org/10.1158/0008-5472.CAN-20-1641

Published: 01 April 2021

View articletitled, MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis

Includes: Supplementary data

Journal Articles

Abstract PO-024: Catastrophic ATP loss underlines a metabolic combination therapy tailored for MYCN-amplified neuroblastoma

Cancer Res (2020) 80 (23_Supplement): PO-024.

https://doi.org/10.1158/1538-7445.EPIMETAB20-PO-024

Published: 02 December 2020

View articletitled, Abstract PO-024: Catastrophic ATP loss underlines a metabolic combination therapy tailored for MYCN-amplified neuroblastoma

Journal Articles

Abstract P1-19-28: Genomic screening reveals UBA1 as a potent and druggable target in diverse models of triple negative breast cancer

Sheeba Jacob, Tia H. Turner, Ann K. Yu, Colin M. Coon, Mohammad A. Alzubi, Charles T. Jakubik, Ynes Bouck, Mikhail G. Dozmorov, Sosipatros A. Boikos, Jennifer Koblinski, Joshua C. Harrell, Cyril H. Benes, Carlotta Costa, Anthony C. Faber

Cancer Res (2020) 80 (4_Supplement): P1-19-28.

https://doi.org/10.1158/1538-7445.SABCS19-P1-19-28

Published: 15 February 2020

View articletitled, Abstract P1-19-28: Genomic screening reveals UBA1 as a potent and druggable target in diverse models of triple negative breast cancer

Journal Articles

Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?

Konstantinos V. Floros, Aaron N. Hata, Anthony C. Faber

Cancer Res (2020) 80 (1): 25–26.

https://doi.org/10.1158/0008-5472.CAN-19-3405

Published: 03 January 2020

View articletitled, Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?

Journal Articles

Abstract 3082: Deficient NOXA in HER2-amplified breast cancer drives kinase inhibitor resistance

Konstantinos V. Floros, Kyung-A Song, Timothy L. Lochmann, Mark T. Hughes, Daniel A. Heisey, Hisashi Harada, Bin Hu, Jennifer Koblinski, Andrew J. Souers, Joel D. Leverson, Anthony C. Faber

Cancer Res (2017) 77 (13_Supplement): 3082.

https://doi.org/10.1158/1538-7445.AM2017-3082

Published: 01 July 2017

View articletitled, Abstract 3082: Deficient NOXA in HER2-amplified breast cancer drives kinase inhibitor resistance

Journal Articles

Abstract 2845: Co-acquisition of T790M and EMT in resistant EGFR mutant non-small cell lung cancer can be overcome by combined irreversible EGFR and BCL-XL inhibition

Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald, Hillary Mulvey, Jungoh Ham, Maria Gomez-Caraballo, Anuj Kalsy, Anthony C. Faber, Jeffrey Engelman

Cancer Res (2015) 75 (15_Supplement): 2845.

https://doi.org/10.1158/1538-7445.AM2015-2845

Published: 01 August 2015

View articletitled, Abstract 2845: Co-acquisition of T790M and EMT in resistant EGFR mutant non-small cell lung cancer can be overcome by combined irreversible EGFR and BCL-XL inhibition

Journal Articles

Abstract 2619: Meausuring PIP3 reveals the unexpected role of p110B in luminal breast cancers

Carlotta Costa, Hiromichi Ebi, Anthony C. Faber, Madhuri Nishtala, Youngchul Song, Cyril H. Benes, Jeffrey A. Engelman

Cancer Res (2014) 74 (19_Supplement): 2619.

https://doi.org/10.1158/1538-7445.AM2014-2619

Published: 01 October 2014

View articletitled, Abstract 2619: Meausuring PIP3 reveals the unexpected role of p110B in luminal breast cancers

Journal Articles

Abstract 4773: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6 dependent survival pathways

Stephen Michael Rothenberg, Kyle Concannon, Sarah Cullen, Alexa B. Turke, Anthony C. Faber, Jeffrey A. Engelman, Shyamala Maheswaran, Daniel A. Haber

Cancer Res (2014) 74 (19_Supplement): 4773.

https://doi.org/10.1158/1538-7445.AM2014-4773

Published: 01 October 2014

View articletitled, Abstract 4773: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6 dependent survival pathways

Journal Articles

Abstract 2933: Assessment of ABT-263 activity across a comprehensive cancer cell line collection leads to a novel, potent combination therapy for small cell lung cancer

Anthony C. Faber, Carlotta Costa, Anahita Dastur, Cyril Benes, Jeffrey Engelman

Cancer Res (2014) 74 (19_Supplement): 2933.

https://doi.org/10.1158/1538-7445.AM2014-2933

Published: 01 October 2014

View articletitled, Abstract 2933: Assessment of ABT-263 activity across a comprehensive cancer cell line collection leads to a novel, potent combination therapy for small cell lung cancer

Journal Articles

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Aaron N. Hata, Alan Yeo, Anthony C. Faber, Eugene Lifshits, Zhao Chen, Katherine A. Cheng, Zandra Walton, Kristopher A. Sarosiek, Anthony Letai, Rebecca S. Heist, Mari Mino-Kenudson, Kwok-Kin Wong, Jeffrey A. Engelman

Cancer Res (2014) 74 (11): 3146–3156.

https://doi.org/10.1158/0008-5472.CAN-13-3728

Published: 29 May 2014

View articletitled, Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Includes: Supplementary data

Journal Articles

Abstract 4568: Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma.

Ryan B. Corcoran, Stephen M. Rothenberg, Aaron N. Hata, Anthony C. Faber, Daniel Winokur, Adriano Piris, Rosalynn M. Nazarian, Ronald D. Brown, Jason T. Godfrey, Mari Mino-Kenudson, Jeffrey Settleman, Jennifer A. Wargo, Keith T. Flaherty, Daniel A. Haber, Jeffrey A. Engelman

Cancer Res (2013) 73 (8_Supplement): 4568.

https://doi.org/10.1158/1538-7445.AM2013-4568

Published: 15 April 2013

View articletitled, Abstract 4568: Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma.

Journal Articles

An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

Birgit Schoeberl, Anthony C. Faber, Danan Li, Mei-Chih Liang, Katherine Crosby, Matthew Onsum, Olga Burenkova, Emily Pace, Zandra Walton, Lin Nie, Aaron Fulgham, Youngchul Song, Ulrik B. Nielsen, Jeffrey A. Engelman, Kwok-Kin Wong

Cancer Res (2010) 70 (6): 2485–2494.

https://doi.org/10.1158/0008-5472.CAN-09-3145

Published: 14 March 2010

View articletitled, An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 1381: BCL-2 selective inhibitor venetoclax combined with topoisomerase I inhibitor irinotecan is effective in small cell lung cancer (SCLC)

A Critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment

The Innate Immune System and the TRAIL–Bcl-XL Axis Mediate a Sex Bias in Lung Cancer and Confer a Therapeutic Vulnerability in Females

Abstract 5976: R9: A novel NuRD complex inhibitor for targeted therapy in triple negative breast cancer (TNBC)

Abstract 5119: Exploring the relationship between metabolism and the epigenome in MYCN-amplified neuroblastoma

Abstract 7071: Pharmacological targeting of SUMOylation leads to cBAF complex stabilization and disruption of the synovial sarcoma signature

Abstract 362: MYCN-amplified neuroblastoma is addicted to iron and vulnerable to ferroptosis

MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis

Abstract PO-024: Catastrophic ATP loss underlines a metabolic combination therapy tailored for MYCN-amplified neuroblastoma

Abstract P1-19-28: Genomic screening reveals UBA1 as a potent and druggable target in diverse models of triple negative breast cancer

Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?

Abstract 3082: Deficient NOXA in HER2-amplified breast cancer drives kinase inhibitor resistance

Abstract 2845: Co-acquisition of T790M and EMT in resistant EGFR mutant non-small cell lung cancer can be overcome by combined irreversible EGFR and BCL-XL inhibition

Abstract 2619: Meausuring PIP3 reveals the unexpected role of p110B in luminal breast cancers

Abstract 4773: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6 dependent survival pathways

Abstract 2933: Assessment of ABT-263 activity across a comprehensive cancer cell line collection leads to a novel, potent combination therapy for small cell lung cancer

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Abstract 4568: Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma.

An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only